Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia
Table 1
Change of parameters before and after intradetrusor NTX treatment of NDO and IDO patients.
Baseline
1 month
3 months
6 months
NDO
MCC (mL)
138.2 ± 13.8
358.8 ± 25.2*
—
—
Pdetmax (cmH2O)
65.9 ± 6.5*
27.3 ± 4.8*
—
—
Frequency
7.53 ± 0.7*
5.71 ± 0.3*
6.31 ± 0.4*
—
Incontinence (times/day)
4.67 ± 0.7*
1.07 ± 1.0*
2.07 ± 0.4*
—
IDO
MCC (mL)
171.8 ± 10.2
319.8 ± 19.4*
—
—
Pdetmax (cmH2O)
63.5 ± 5.0*
32.3 ± 4.4*
—
—
Frequency
13.7 ± 0.6*
11.4 ± 0.7*
11.2 ± 0.7*
10.5 ± 0.9*
Incontinence (times/day)
4.46 ± 0.5*
1.49 ± 0.4*
1.82 ± 0.4*
2.28 ± 0.7*
*Compared with baseline, . MCC: maximum cystometric capacity; Pdetmax: maximum detrusor pressure at detrusor overactivity.
